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Abstract  
Background: The survival rates for patients diagnosed with uveal melanoma in Australia are 
unknown. Few long-term studies of uveal melanoma are available, and it is unclear whether 
their results are applicable to the Australian population. 
Design: Retrospective population-based study 
Participants: Patients diagnosed with uveal melanoma between 1981 and 2005 in Western 
Australia. 
Methods: 308 cases were included. Relative survival and Cox regression were performed. 
Variables tested for their predictive ability included patient age and sex, tumour-specific 
variables and treatment modality.  
Main Outcome Measures: All cause survival rates and relative survival rates of patients with 
diagnosed uveal melanoma. 
Results: Relative survival rates for the entire cohort were 88.2%, 81.4% and 71.4% at 3-, 5- 
and 10-years respectively. Predictors of worse survival included mixed-cell tumour 
morphology (HR = 2.1; p-value = 0.002), tumour location at the ciliary body (HR = 1.7; p-value 
= 0.029)  and tumour apical height more than 5mm (HR 1.9, p-value  = 0.026).  Of all patients 
who underwent enucleation, those diagnosed in 1998-2005 died twice as fast (HR  = 2.3; p-
value = 0.004). In the 17 patients with metastasis median survival time from date of diagnosis 
of metastasis was 3.1 months. 
Conclusions: These survival estimates are comparable to those reported for the United States, 
and more optimistic than those reported for most European-based studies. Tumour apical 
height, tumour site, tumour morphology and having an enucleation in certain calendar 
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periods of diagnosis were independent predictors of survival. Survival prognosis for patients 
with diagnosed metastatic uveal melanoma is very poor. 
Key words: Uveal melanoma, Survival, Intraorbital malignancy 
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Background  
Uveal melanoma (UM) is the most common primary intraocular malignancy.1 with an 
incidence of 9.8 per million population per year in Australia .2 This rate is higher than those 
reported from the USA3 and Europe4-6  
UM is most common in Caucasians, and is rare in pigmented races7. UM is fatal in 
approximately 50% of patients, due to metastatic disease, usually to the liver. Despite the 
many advances in diagnosis and treatment of the primary tumour in recent years, there has 
been no improvement in survival rates8, 9 and median survival time following diagnosis with 
metastasis remains poor10, even with adjuvant therapy. 
Methods 
This study was a retrospective population-based cohort study of all persons diagnosed with 
UM in Western Australia for the time period 1981-2005. Only patients who were residents of 
Western Australia at the time of diagnosis were included in the analysis.  Ethics approval was 
obtained from two independent Human Research Ethics Committees.  
Cases were sourced primarily from the Western Australia Cancer Registry (WACR) where all 
cases of cancers in Western Australia are legally required to be reported. Cases were identified 
the ICD-10-O Version 3 site and morphology code combinations specific for uveal melanoma. 
Only cases of UM (including iris, choroid and ciliary body) with a date of diagnosis from 1 
January 1981 and 31 December 2005 were included. 
The recruitment of cases was supplemented by review of medical physics files of all patients 
who had episcleral Cobalt-60- and Iodine-125-seeded radioactive plaque therapy between 
1981 and 2005 at the Royal Perth Hospital Medical Physics department. Ophthalmic 
brachytherapy in Western Australia has been exclusively carried out at Royal Perth Hospital 
since its inception in Western Australia in the 1980s. Where available, accompanying clinical 
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information on size and location of the tumour were noted and entered into a Microsoft 
Access database. Tumours were grouped according to Callender’s histological groupings11. 
This supplementary clinical data were crosschecked against the WACR and used to identify 
additional cases that were not adequately notified to the WACR and to record additional 
tumour details on notified cases where possible.  Death information of the identified cases 
was extracted from the state based death registry by the Data Linkage Branch of the Western 
Australia Department of Health (WA Health).  
Survival outcomes for the cohort were investigated using relative survival estimation and 
proportional hazards regression models.  Analysis time was from date of diagnosis until date 
of death or the study censor date of 31 December 2008 for patients still alive at this date.  
Relative survival analysis was performed to estimate tumour-specific survival. This method 
adjusts for competing causes of death by estimating the excess mortality associated with a 
cancer diagnosis over and above what mortality might be expected in a similar population 
who are assumed to be free of the cancer of interest.12 Relative survival is estimated from life 
tables as the ratio of the observed survival of the patients to the expected survival in an age-
, sex- and calendar period-matched population. Relative survival analysis using the Ederer II 
methodology was performed using the stnet command13 based in Stata with life tables of the 
Australian population obtained from the Australian Bureau of Statistics. Stratified relative 
survival estimates and 95% confidence intervals were obtained by age group, sex, tumour 
histology, tumour site, treatment modality, tumour size and calendar period of diagnosis, and 
graphs produced. 
Explanatory factors associated with all-cause mortality patients with UM were explored using 
multivariate Cox proportional hazards models.14 Data were formatted using the counting 
process method with enucleation status entered as a time-dependent variable. Potential 
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predictors and confounders were age at diagnosis, calendar period of diagnosis, gender and 
all tumour-specific and treatment variables.   Likelihood ratio tests were used to include or 
exclude covariates from the adjusted model and to identify any potential plausible interaction 
terms at the 5% significance level.  A test for violation of the proportional hazards assumption 
was performed on the final model using Schoenfeld residuals.  All analyses were performed 
using Stata 13 (StataCorp, College Station Tx). 
Results 
There were 309 Western Australian residents diagnosed with UM during the period 1981-
2005. Of these, 299 cases were identified on the WACR and an additional 10 cases were 
identified from review of medical physics records that had not been notified to the WACR as 
UM. One case was excluded due to “zero survival”- that is, they were diagnosed with their UM 
at death, leaving 308 cases to be included. 
The demographic and tumour characteristics of the cases are summarised in Table 1. There 
was an equal distribution of males and females amongst the cohort.  The median age at 
diagnosis of UM was 61.6 years. Minimum and maximum ages at diagnosis were 16 years and 
93 years respectively.  Accurate tumour site sub-classification was achieved for 86% (n=266) 
cases.  Details regarding the maximum diameter and apical height of the tumour were 
available in 148 cases and tumour histology was available for 151 cases.  Most tumours were 
located in the choroid and around a quarter of the cohort had tumours greater than 1cm in 
diameter at time of diagnosis.  There was a tendency for cases to be diagnosed in the more 
recent calendar periods. 
Just over half of all cases (n = 158; 51%) died during the follow-up period.  Median survival 
time for the entire cohort was 11.6 years (95% CI: 9.1, 14.1).  Univariate Log –rank tests for 
equality of survivorship function showed that tumour histology was associated with all cause 
survival outcomes and there was evidence of a weak association of tumour apical height with 
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all-cause survival outcomes (Table 1).  As expected, increasing age was associated with shorter 
overall survival. 
The 3, 5 and 10 year overall survival proportions for the whole cohort were 83%, 73% and 56% 
respectively.  When life tables were used to account for the baseline death rates in the general 
population, the relative survival rates at 3-, 5- and 10- years were 88% (95% CI: 83%-92%), 
81% (95%CI: 76% - 87%) and 71% (95%CI 63% -78%) respectively.  Relative survival proportions 
at 3, 5 and 10 years post diagnosis by demographic and tumour characteristics are shown in 
Table 2.   After taking the background death rate of the general population, increasing age at 
diagnosis, having a ciliary location, a larger basal diameter and epithelial or mixed morphology 
were generally associated with poorer relative survival outcomes.  No difference in relative 
survival outcomes were observed by gender.  Cases diagnosed prior to 1990 tended to have 
better relative survival outcomes. Graphical representation of the relative survival outcomes 
by tumour morphology are shown in Figure` 1 and demonstrate a survival advantage of 
spindle cell melanomas compared to epitheliod or mixed cell type morphologies. 
Multivariate survival regression models were constructed to determine if the survival 
advantage for spindle cell melanomas remained after taking other tumour information and 
patient demographic variables into account (Table 3).  Spindle cell melanomas were found to 
have half the rate of dying compared to patients diagnosed with mixed cell morphology. There 
was a trend for spindle cell morphology to have a survival advantage compared with 
epitheliod cell types but this did not reach statistical significance in this study.  
The multivariate model also showed that being diagnosed in more recent calendar periods 
was associated with poorer survival outcomes but only after a patient had undergone an 
enucleation. Patients diagnosed 1998-2005 and who underwent enucleation died more than 
twice as quickly as those who were diagnosed in 1981-1989 and had an enucleation.  In 
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contrast, there was no difference in survival outcomes for patients diagnosed in 1981-1989 
compared to those diagnosed in 1998-2005 for patients who had not undergone an 
enucleation. However, there was moderate evidence of poorer survival for patients who had 
not undergone enucleation if they were diagnosed in the middle period of the study. 
Other clinical features found to be associated with survival outcomes and after adjusting for 
age and year and enucleation status were apical height and site. A recorded apical height 
greater than 5 mm was associated with 90% increased rate of death compared to patients 
with tumours less than 5 mm.  Diagnosis of a ciliary body tumour bestowed a 70% increased 
hazard rate when compared to all other tumours.  Patients who underwent brachytherapy 
showed no survival advantage compared to patients who did not receive brachytherapy. Basal 
diameter and patient gender were not associated with survival outcomes in this study. 
In this patient series, there were 18 cases in which details regarding tumour metastasis were 
collected. One case had disseminated UM with liver involvement diagnosed at death, so was 
not included for analysis. Of the remaining 17 cases, 16 had died by the censor date. Liver 
involvement occurred in 16 of the 17 cases. The median time to metastasis was 3.3 years, but 
metastases were diagnosed up to 10.1 years after diagnosis of UM. Median survival time from 
date of diagnosis of metastasis was just 3.1 months in the 17 patients, with a range of 1 day 
to 14.3 years. 
Discussion 
This study’s 5-year relative survival estimate of patients with UM is comparable to that 
reported in the United States8, but more optimistic that the estimates provided in Danish15, 
Finnish16, European17 and British18 studies. The differences in the rates may be at least in part 
due to disparities between countries in the reporting practices to the relevant registries. 
Interestingly, in a worldwide population based study19 comparing relative survival from major 
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cancers across 5 continents, Australian patients were found to have significantly better 
survival in all the studied cancers  than Europe as a whole, and was found to have more 
favourable survival than the UK when it is considered in isolation. When compared to North 
America, Australia had very similar relative survival rates for all but one of the major cancers 
analysed. Hence the results and inter-country comparisons of survival estimates for UM in this 
study seem to parallel that for most major cancers. 
The results from multivariate Cox models showed that tumours at the ciliary body bestowed 
a significantly increased rate of death from all causes when compared to all other tumours 
(including iris melanomas and those tumours for which site sub-classification was not 
achieved). Ciliary body involvement has been associated with increased mortality in a number 
of other studies20. When McLean et al.21 investigated survivorship according to tumour 
location it was shown that in their series of patients, ciliary body involvement was determined 
by the location of the anterior tumour margin, and that the greater rate of tumour-related 
mortality was for the most part attributable to their larger size and more malignant cytology. 
Ciliary body tumours are more likely to be diagnosed later due to their location and hence, 
are larger at presentation. 
Tumour apical height and histology exerted a demonstrable independent effect on survival. 
Tumour thickness was categorised as a high risk clinical prognostic factor in a review of 
prognostic parameters undertaken by Mooy and De Jong20. Tumour LBD was not a significant 
predictor in our multivariate analysis, which agrees with Mooy and De Jong’s suggestion that 
tumour thickness is a more reliable prognostic parameter. Unfortunately, the limited number 
of cases for which tumour dimensions were obtained meant that categorisation according to 
the COMS criteria of tumour size would have rendered comparisons between the groups 
unreliable. This of course makes more extensive inter-study comparison difficult.  
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Any tumour that comprised a component of epithelioid-cell morphology appeared to be 
associated with increased mortality, with the relative survival table showing that spindle-cell 
melanomas were associated with better survivorship. However, the number of cases with 
histological data was too small to show that its trend towards better survival was significant. 
On inspection of the survival data presented in our study the group of cases for which tumour 
diameter information was not obtained had similar relative survival trends to the >10mm 
tumour diameter group. An explanation for this is that accurate tumour measurements may 
have been less likely to be recorded for larger-sized tumours, particularly where enucleation 
is considered as the primary treatment. Unlike enucleation, conservative therapies including 
local excision or plaque brachytherapy require an accurate description of tumour dimensions. 
Thus tumour diameter information is more likely to be complete for smaller tumours as they 
are more likely to be treated by conservative methods. This would create in the “unknown” 
group, a profile of tumour diameter that would closer resemble that of the “>10mm” group.  
The finding of poorer survival outcomes for patients diagnosed in more recent calendar 
periods and after undergoing enucleation is most likely a reflection of the use of enucleation 
as primary treatment in earlier time periods but more of a last resort treatment in more recent 
calendar periods.  We could not confirm this hypothesis by estimating tumour stage at 
enucleation due to the lack of tumour details for a large number of patients, a limitation of 
this study.   An interesting observation was that patients diagnosed 1990-1997 who did not 
undergo enucleation tended to have poorer survival outcomes. Most other comparable 
studies show little to no change in survival rates over time8, 15, 17, 18, with the Swedish study22 
reporting an improvement in survival rates with diagnosis in more recent time periods.  
In the 17 cases where metastasis was diagnosed before death, median survival time was 3.1 
months. The identification of metastatic cases in our series of patients was somewhat crude 
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and incomplete such that our study probably identified more clinically obvious and 
progressive metastases. Thus it is not representative of survival in those patients with 
metastatic disease. 
Case identification in this study is likely to have been incomplete, particularly for smaller 
melanomas of the uvea which are more likely to have been treated by more conservative 
methods including transpupillary thermotherapy and laser photocoagulation. Such 
treatments can be carried out as part of routine consultations in ophthalmology clinics across 
the state. This puts these cases at risk of non-notification to the Western Australia Cancer 
Registry and at risk of non-assessment at a major metropolitan teaching hospital. This may 
weaken the ability to extend the results of our study to those patients with a small UM. 
Our data could not fully explain the survival disadvantage that was bestowed by being 
diagnosed in more recent time periods for patients who underwent enuclation. It is likely that 
enucleation has only been performed for more advanced tumours in the later years. More 
adequate completion of data fields for many of the covariates investigated in our study may 
reveal a time-dependent change that could explain the paradoxical trend over time.  Another 
possible explanation for this observation is a change in notification practices over time.  
In future, it is likely that clinicopathological features of uveal melanoma will assume lesser 
significance in clinical management. Recent developments in prognostic testing in uveal 
melanoma include the identification of cytogenetic markers, gene expression profiling, and 
the identification of specific driver mutations. Such discoveries offer the prospect of targeted 
therapy to those patients at greatest risk of metastatic disease and death.23, 24  
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Table 1.  Summary characteristics of the overall cohort (n=308) and tests for equality of survivorship 
function for each characteristic. 
 
 Total cases  Alive  Died Log-rank 
 N %  N %  N % p-value 
Age at diagnosis          
<50 years 82 26.6  65 43.3  17 10.8 
<0.001 
50-60 years 68 22.1  42 28.0  26 16.5 
61-70 years 78 25.3  29 19.3  49 31.0 
>70 years 80 26.0  14 9.3  66 41.8 
          
Year of diagnosis          
1981-1989 88 28.6  33 22.0  55 34.8 
0.123 1990-1997 103 33.4  40 26.7  63 39.9 
1998-2005 117 38.0  77 51.3  40 25.3 
          
Sex          
Male 162 52.6  80 53.3  82 51.9 
0.789 
Female 146 47.4  70 46.7  76 48.1 
          
Tumour site          
Choroid 229 74.4  113 75.3  116 73.4 
0.156 Ciliary 33 10.7  12 8.0  21 13.3 
Iris /Unknown 46 14.9  25 16.7  21 13.3 
          
Largest basal diameter          
<=10mm 69 22.4  40 26.7  29 18.4 
0.083 >10mm 79 25.6  45 30.0  34 21.5 
Unknown 160 51.9  65 43.3  95 60.1 
          
Apical height          
<=5mm 59 19.2  36 24.0  23 14.6 
0.187 >5mm 80 26.0  45 30.0  35 22.2 
Unknown 169 54.9  69 46.0  100 63.3 
          
Histology          
Epitheliod 15 4.9  2 1.3  13 8.2 
<0.001 
Spindle 87 28.2  40 26.7  47 29.7 
Mixed 49 15.9  16 10.7  33 20.9 
Unknown 157 51.0  92 61.3  65 41.1 
          
Brachytherapy          
No 240 77.9  99 66.0  141 89.2 
0.027 
Yes 68 22.1  51 34.0  17 10.8 
          
Enucleation          
No 133 43.2  78 52.0  55 34.8 
0.003 
Yes 103 56.8  72 48.0  103 65.2 
          
Total 308   150   158   
 
Table 2.  Relative survival proportions alive at 3, 5 and 10 years post diagnosis for the uveal melanoma 
cohort (n=308) stratified by demographic and tumour characteristics and estimated using the Ederer II 
method. 
 
 3 years  5 years  10 years 
 % 95% CI  % 95% CI  % 95% CI 
Age at diagnosis               
<50 years 99 92 - 100  93 84 - 97  83 72 - 91 
50-60 years 95 86 - 99  83 70 - 91  72 56 - 84 
61-70 years 80 68 - 88  74 61 - 84  64 48 - 78 
>70 years 78 65 - 89  74 59 - 87  62 42 - 83 
               
Year of diagnosis               
1981-1989 91 81 - 97  88 78 - 96  85 71 - 95 
1990-1997 86 76 - 93  76 64 - 85  62 49 - 74 
1998-2005 88 79 - 94  80 70 - 88  67 50 - 81 
               
Sex               
Male 87 80 - 93  80 72 - 87  71 60 - 81 
Female 89 82 - 95  82 73 - 89  71 60 - 81 
               
Tumour site               
Choroid 91 86 - 95  84 77 - 89  73 63 - 81 
Ciliary 75 55 - 89  64 43 - 80  57 35 - 76 
Iris /Unknown 83 66 - 94  79 61 - 92  73 51 - 90 
               
Largest basal diameter               
<=10mm 100 90 - 103  103 92 - 107  89 72 - 103 
>10mm 87 76 - 95  75 62 - 85  69 54 - 82 
Unknown 84 76 - 90  75 66 - 82  65 54 - 75 
               
Apical height               
<=5mm 97 86 - 102  95 82 - 103  82 62 - 98 
>5mm 91 81 - 98  86 74 - 94  77 61 - 90 
Unknown 83 76 - 89  74 65 - 81  65 55 - 74 
               
Histology               
Epitheliod 75 42 - 95  58 26 - 85  34 8 - 72 
Spindle 93 83 - 99  89 78 - 97  70 55 - 83 
Mixed 75 59 - 86  59 43 - 73  50 34 - 66 
Unknown 91 84 - 96  86 77 - 92  83 72 - 92 
               
Brachytherapy               
No 85 75 - 90  77 70 - 83  68 59 - 76 
Yes 96 85 - 100  92 79 - 99  70 49 - 87 
               
Enucleation               
No 89 80 - 94  81 71 - 89  75 62 - 86 
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Relative survival by histology
Table 3.  Relative rates of death in the uveal melanoma cohort as estimated from a multivariate Cox 
regression model with enucleation status entered as a time-dependent covariate and as an interaction 
term with diagnosis period. 
 
 
 Hazard ratio 95% CI p-value 
Age at diagnosis    
< 50 years 1 ref  
50-60 years 2.1 1.1-3.9 0.023 
61-70 years 4.6 2.6-8.1 <0.001 
>70 years 7.7 4.4-13.5 <0.001 
    
Morphology    
Spindle 1 ref  
Epitheliod 1.6 0.8-3.1 0.204 
Mixed 2.1 1.3-3.5 0.002 
Unknown 1.1 0.7-1.8 0.574 
    
Apical height    
<5 mm 1 ref  
>5 mm 1.9 1.1-3.3 0.026 
Unknown 2.1 1.2-3.6 0.001 
    
Site    
Choroid 1 ref  
Ciliary 1.7 1.1-2.9 0.029 
Iris or unknown 1.0 0.6-1.6 0.945 
    
Brachytherapy    
No 1 ref  
Yes 0.9 0.5-1.8 0.813 
    
No  enucleation    
1981-1989 1 ref  
1990-1997 2.0 1.1-4.0 0.036 
1998-2005 1.0 0.4-2.4 0.955 
    
After enucleation    
1981-1989 1 ref  
1990-1997 1.8 1.1-3.0 0.024 
1998-2005 2.3 1.3-4.0 0.004 
 
 
